Diclofenac Potassium Liquid Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diclofenac potassium, a potent NSAID, faces challenges in bioavailability and chemical stability when dissolved in water due to its pH-dependent solubility and susceptibility to oxidative degradation, limiting the development of effective liquid oral formulations that are also palatable.
Innovation Solution
A ready-to-use liquid formulation of diclofenac potassium or its pharmaceutically acceptable salt is created, comprising xylitol, water, and optionally sorbitol, with specific ratios and additional ingredients like alkalizing agents, thickeners, and flavoring agents, to enhance bioavailability, stability, and palatability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If diclofenac potassium is dissolved in water to create a liquid formulation, then bioavailability and patient convenience are improved, but chemical stability deteriorates due to oxidative degradation
Solution Approach 1:
The patent uses xylitol and sorbitol as intermediary substances that stabilize diclofenac potassium in liquid formulation. These polyols act as protective mediators between the drug and water, preventing oxidative degradation while maintaining solubility and bioavailability.
Solution Approach 2:
The patent creates an inert aqueous environment by using xylitol and sorbitol solutions instead of pure water. This inert environment protects diclofenac potassium from oxidation while still allowing it to remain dissolved and bioavailable.
2Quantity of substance
If diclofenac potassium is dissolved in water, then solubility increases, but chemical stability worsens due to pH-dependent oxidative degradation
Solution Approach 1:
The patent changes the pH parameter of the dissolution medium by using xylitol and sorbitol solutions with specific pH characteristics. This pH modification increases solubility while simultaneously reducing oxidative degradation, resolving the contradiction between solubility and stability.
3Ease of operation
If liquid formulation is developed for diclofenac potassium, then patient compliance and convenience are improved, but palatability deteriorates due to bitter taste
Solution Approach 1:
The patent uses xylitol and sorbitol as intermediary substances that mask the bitter taste of diclofenac potassium. These polyols act as taste-modifying mediators that preserve the therapeutic benefits of the liquid formulation while eliminating the palatability problem.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high bioavailability, chemical stability, and palatability, as demonstrated by stability data showing minimal impurity levels and consistent pH over time, with the Lamiflex 4 material proving suitable for packaging, ensuring effective pain management and migraine treatment.
Implementation Method 1
the molecule could be expected to undergo a fast and irreversible oxidative degradation according to the auto-oxidation pathway
Implementation Method 2
The solubility of diclofenac potassium (pKa=3.9) is pH dependent. It is sparingly soluble at acidic pH, and the amount of the active substance dissolved in buffered solutions increases with the increasing pH of the dissolution aqueous medium.
Data Source
AI summary
Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs.